Synthesis, structural characterization, biological evaluation and molecular docking studies of new platinum(II) complexes containing isocyanides

Herein, new Pt(II) complexes [R′2Pt(CNR)2] (1a–c; R′ = Me and 2a–c; R′ = p-tolyl) were synthesized by the reaction of the precursor complexes cis,cis-[Me2Pt(μ-SMe2)2PtMe2], A, and cis-[(p-tolyl)2Pt(SMe2)2], B, with four and two equivalents of different types of isocyanide ligands (CNR; R = a; t-butyl, b; benzyl, and c; cyclohexyl isocyanide), respectively. All complexes were characterized by FTIR and NMR spectroscopies, and the structure of 2b was confirmed by single-crystal X-ray determination. The evaluation of the cytotoxicity of 1a–c and 2a–c against three human cancer cell lines, namely A549 (non-small cell lung cancer cell line), SKOV3 (human ovarian cancer cell line), and MCF-7 (human breast cancer cell line), revealed promising antitumor activities for 1b and 2a in comparison with that of the standard cisplatin. Moreover, 1b effectively rendered apoptosis-inducing activities to the MCF-7 cancer cell line. The electrophoresis mobility shift assays on plasmids as well as molecular docking studies on DNA structures effectively revealed the specific binding site, binding mode, and the best orientation of the complexes to DNA.

[1]  H. R. Shahsavari,et al.  Cycloplatinated(II) complexes bearing 1,1′-bis(diphenylphosphino)ferrocene ligand: biological evaluation and molecular docking studies , 2018 .

[2]  G. Deacon,et al.  Synthesis and antiproliferative activity of a series of new platinum and palladium diphosphane complexes. , 2018, Dalton transactions.

[3]  Ž. Bugarčić,et al.  Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives. , 2017, European journal of medicinal chemistry.

[4]  Saeed Ahmad,et al.  Kinetic aspects of platinum anticancer agents , 2017 .

[5]  V. Brabec,et al.  Cytotoxic platinum coordination compounds. DNA binding agents , 2017 .

[6]  Bo Yang,et al.  Research progress in modern structure of platinum complexes. , 2017, European journal of medicinal chemistry.

[7]  M. Edirisinghe,et al.  Drug Delivery Strategies for Platinum-Based Chemotherapy. , 2017, ACS nano.

[8]  O. Kanat,et al.  Platinum-induced neurotoxicity: A review of possible mechanisms , 2017, World journal of clinical oncology.

[9]  H. R. Shahsavari,et al.  Combined Kinetico‐Mechanistic and Theoretical Elucidation of the Oxidative Addition of Iodomethane to Cycloplatinated(II) Complexes: Controlling the Rate of trans/cis Isomerization , 2017 .

[10]  H. R. Shahsavari,et al.  Photophysical properties of a series of cycloplatinated(II) complexes featuring allyldiphenylphosphane , 2017 .

[11]  E. Rybalka,et al.  Neurotoxicity Associated with Platinum-Based Anti-Cancer Agents: What are the Implications of Copper Transporters? , 2017, Current medicinal chemistry.

[12]  H. R. Shahsavari,et al.  Cyclometalated Platinum(II) Complexes Comprising 2‐(Diphenylphosphino)pyridine and Various Thiolate Ligands: Synthesis, Spectroscopic Characterization, and Biological Activity , 2017 .

[13]  S. Zare,et al.  A comparative QSAR analysis and molecular docking studies of phenyl piperidine derivatives as potent dual NK1R antagonists/serotonin transporter (SERT) inhibitors , 2017, Comput. Biol. Chem..

[14]  C. Marmion,et al.  Platinum(IV) Prodrugs – A Step Closer to Ehrlich's Vision? , 2017 .

[15]  H. Ohmiya,et al.  Synthesis of α-Quaternary Formimides and Aldehydes through Umpolung Asymmetric Copper Catalysis with Isocyanides. , 2017, Journal of the American Chemical Society.

[16]  H. Sadeghpour,et al.  Binding mode of triazole derivatives as aromatase inhibitors based on docking, protein ligand interaction fingerprinting, and molecular dynamics simulation studies , 2017, Research in pharmaceutical sciences.

[17]  R. Gust,et al.  Update on metal N-heterocyclic carbene complexes as potential anti-tumor metallodrugs , 2016 .

[18]  G. Deacon,et al.  Labile Pd-sulphur and Pt-sulphur bonds in organometallic palladium and platinum complexes [(COD)M(alkyl)(S-ligand)]n+-A speciation study. , 2016, Journal of inorganic biochemistry.

[19]  H. R. Shahsavari,et al.  A cooperative pathway for water activation using a bimetallic Pt0-CuI system. , 2016, Dalton transactions.

[20]  S. Lippard,et al.  Chemical Approach to Positional Isomers of Glucose-Platinum Conjugates Reveals Specific Cancer Targeting through Glucose-Transporter-Mediated Uptake in Vitro and in Vivo. , 2016, Journal of the American Chemical Society.

[21]  Sourav Bagchi,et al.  Isocyanide based [4+1] cycloaddition reactions: an indispensable tool in multi-component reactions (MCRs). , 2016, Chemical communications.

[22]  S. Gómez‐Ruiz,et al.  Nanostructured materials functionalized with metal complexes: In search of alternatives for administering anticancer metallodrugs , 2016 .

[23]  S. Tabassum,et al.  Current and future potential of metallo drugs: Revisiting DNA-binding of metal containing molecules and their diverse mechanism of action , 2016 .

[24]  M. Bode,et al.  Synthesis, Reactions and Uses of Isocyanides in Organic Synthesis. An Update , 2016 .

[25]  S. Lippard,et al.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. , 2016, Chemical reviews.

[26]  J. Pichel,et al.  Luminescent pentafluorophenyl-cycloplatinated complexes: synthesis, characterization, photophysics, cytotoxicity and cellular imaging. , 2015, Dalton transactions.

[27]  Z. Dvořák,et al.  Dichlorido-platinum(II) complexes with kinetin derivatives as promising cytotoxic agents avoiding resistance of cancer cells: Contrasting results between cisplatin and oxaliplatin analogues , 2015 .

[28]  Yan Peng,et al.  Stabilization of G-quadruplex DNA, inhibition of telomerase activity, and tumor cell apoptosis by organoplatinum(II) complexes with oxoisoaporphine. , 2015, Journal of medicinal chemistry.

[29]  C. Janiak,et al.  Dual antitumor and antiangiogenic activity of organoplatinum(II) complexes. , 2015, Journal of medicinal chemistry.

[30]  P. Tchounwou,et al.  Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.

[31]  A. Casini,et al.  Cellular Transport Mechanisms of Cytotoxic Metallodrugs: An Overview beyond Cisplatin , 2014, Molecules.

[32]  U. Schepers,et al.  Cytotoxicity and NMR Studies of Platinum Complexes with Cyclooctadiene Ligands , 2014 .

[33]  A. Isab,et al.  Tetrakis(1-3-diazinane-2-thione)platinum(II) chloride monohydrate complex: Synthesis, spectroscopic characterization, crystal structure and in vitro cytotoxic activity against A549, MCF7, HCT15 and HeLa human cancer lines , 2014 .

[34]  C. Orvig,et al.  Metallodrugs in medicinal inorganic chemistry. , 2014, Chemical reviews.

[35]  P. Pastore,et al.  Platinum(II) Complexes with Novel Diisocyanide Ligands: Catalysts in Alkyne Hydroarylation , 2013 .

[36]  Justin J. Wilson,et al.  Synthetic methods for the preparation of platinum anticancer complexes. , 2013, Chemical reviews.

[37]  A. Klein,et al.  Strong Cytotoxicity of Organometallic Platinum Complexes with Alkynyl Ligands , 2013 .

[38]  E. Lalinde,et al.  New Trans-Configured Acetylide–Cyanide Platinum(II) Anions: Spectroscopic and Optical Studies , 2013 .

[39]  V. Nenajdenko.  Isocyanide Chemistry: Applications in Synthesis and Material Science , 2012 .

[40]  M. Shamsipur,et al.  Affinity of two novel five-coordinated anticancer Pt(II) complexes to human and bovine serum albumins: a spectroscopic approach. , 2012, Inorganic chemistry.

[41]  Z. Amirghofran,et al.  Synthesis, characterization and antitumor activity study of some cyclometalated organoplatinum(II) complexes containing aromatic N-donor ligands , 2011 .

[42]  S. Fricker.  Medicinal Organometallic Chemistry , 2011 .

[43]  Q. Dou,et al.  In vitro and in vivo antitumor activities and DNA binding mode of five coordinated cyclometalated organoplatinum(II) complexes containing biphosphine ligands. , 2011, Journal of medicinal chemistry.

[44]  G. Gasser,et al.  Organometallic Anticancer Compounds , 2010, Journal of medicinal chemistry.

[45]  F. Heinrich,et al.  Organometallic palladium and platinum complexes with strongly donating alkyl coligands – Synthesis, structures, chemical and cytotoxic properties , 2010 .

[46]  Xiaoyong Wang.  Fresh platinum complexes with promising antitumor activity. , 2010, Anti-cancer agents in medicinal chemistry.

[47]  F. Rominger,et al.  New and Easily Accessible Nitrogen Acyclic Gold(I) Carbenes: Structure and Application in the Gold‐Catalyzed Phenol Synthesis as well as the Hydration of Alkynes , 2010 .

[48]  P. Sadler,et al.  Metals in Medicine: Therapeutic Agents , 2009 .

[49]  M. Schäfer,et al.  Organoplatinum(II) and -palladium(II) Complexes of Nucleobases and Their Derivatives , 2009 .

[50]  Dik‐Lung Ma,et al.  Platinum(II) complexes with dipyridophenazine ligands as human telomerase inhibitors and luminescent probes for G-quadruplex DNA. , 2009, Journal of the American Chemical Society.

[51]  Christian G Hartinger,et al.  Bioorganometallic chemistry--from teaching paradigms to medicinal applications. , 2009, Chemical Society reviews.

[52]  Howard L McLeod,et al.  Platinum neurotoxicity pharmacogenetics , 2009, Molecular Cancer Therapeutics.

[53]  P. Sadler,et al.  New trends for metal complexes with anticancer activity. , 2008, Current opinion in chemical biology.

[54]  T. Hambley.  Metal-Based Therapeutics , 2007, Science.

[55]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[56]  W. Price,et al.  195Pt NMR--theory and application. , 2007, Chemical Society reviews.

[57]  M. J. Irwin,et al.  Platinum(II) complexes of dimethyl sulfide , 2007 .

[58]  Robin Taylor,et al.  Mercury: visualization and analysis of crystal structures , 2006 .

[59]  T. Storr,et al.  Design of targeting ligands in medicinal inorganic chemistry. , 2006, Chemical Society reviews.

[60]  Mika Kettunen,et al.  Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin. , 2006, Current medicinal chemistry.

[61]  A. Klein,et al.  On the Borderline between cis and trans in Organometallic (Phosphane)platinum(II) Complexes , 2005 .

[62]  W. Kaim,et al.  Multiple Isomerism (cis / trans; syn / anti) in [(dmso)~2Pt(aryl)~2] Complexes: A Combined Structural, Spectroscopic, and Theoretical Investigation , 2005 .

[63]  M. Jennings,et al.  Dimethylplatinum (II) complexes with isocyanocoumarin ligands: the crystal structure of cis-dimethylbis-(7-diethylamino-3-isocyanocoumarin)platinum(II) , 2005 .

[64]  P. Sgarbossa,et al.  The Staudinger reaction of platinum(II)- and palladium(II)-coordinated 2-(azidomethyl)phenyl isocyanide. X-ray structure of trans-[PtCl{(H)}(PPh3)2][BF4] · CDCl3 · H2O , 2004 .

[65]  M. Hong,et al.  Synthesis, structure, and liquid crystal properties of a series of platinum(II) complexes containing chiral 4-(4-alkoxyphenylethynyl) phenylisocyanide ligands , 2003 .

[66]  S. Lippard,et al.  New metal complexes as potential therapeutics. , 2003, Current opinion in chemical biology.

[67]  F. Wiesbrock,et al.  Gold(I) thiosulfonate complexes , 2003 .

[68]  K. R. Mann,et al.  Characterization of a cross-reactive electronic nose with vapoluminescent array elements. , 2002, Analytical chemistry.

[69]  T. Hambley,et al.  Preparation and cell growth inhibitory activity of [PtR(2)L(2)] (R=polyfluorophenyl, L(2)=diene, cyclohexane-1,2-diamine (chxn) or cis-(dimethyl sulfoxide)(2)) and the X-ray crystal structure of [Pt(C(6)F(5))(2)(cis-chxn)]. , 2002, Journal of inorganic biochemistry.

[70]  K. R. Mann,et al.  Synthesis and characterization of Pt(CN-p-(C(2)H(5))C(6)H(4))(2)(CN)(2), a crystalline vapoluminescent compound that detects vapor-phase aromatic hydrocarbons. , 2002, Journal of the American Chemical Society.

[71]  K. R. Mann,et al.  An electronic nose transducer array of vapoluminescent platinum(II) double salts. , 2001, Journal of the American Chemical Society.

[72]  R. Puddephatt,et al.  Aryldiplatinum(II) Complexes Containing Dimethyl Sulfide and Bis(diphenylphosphino)methane as Bridging Ligands , 2000 .

[73]  Louis J. Farrugia,et al.  WinGX suite for small-molecule single-crystal crystallography , 1999 .

[74]  P. Sadler,et al.  Metals in Medicine. , 1999, Angewandte Chemie.

[75]  W. Schneider,et al.  (Isocyanide)gold(I) Thiosalicylates: Supramolecular Assembly Based on both Auriophilic and Hydrogen Bonding , 1996 .

[76]  M. N. Burnett,et al.  ORTEP-III: Oak Ridge Thermal Ellipsoid Plot Program for crystal structure illustrations , 1996 .

[77]  Sujit Roy,et al.  Two forms of cis-dimethylbis(methyl isocyanide)platinum(II) , 1994 .

[78]  G. Whitesides,et al.  Isotopic exchange reactions occurring in the hydrogenation of (1,5-cyclooctadiene)dialkylplatinum(II) complexes over platinum black , 1988 .

[79]  R. D. Berry,et al.  Oxidative addition to bis(trifluoromethyl)platinum(II) complexes with N-donor ligands , 1988 .

[80]  Keith H. Johnson,et al.  Reductive Elimination of H-H, H-CH3, and CH3-CH3 from Bis(Phosphine)Platinum(II), - Palladium(II), and -Nickel(II) Complexes: A Theoretical Study Using the SCF-X alpha-SW Method. , 1982 .

[81]  Howard C. Clark,et al.  The trans-influence: its measurement and significance , 1973 .

[82]  D. Rabinovich,et al.  Calculation of absorption corrections for camera and diffractometer data , 1965 .

[83]  H. R. Shahsavari,et al.  Synthesis , biological evaluations and molecular docking studies on DNA binding interaction of platinum ( II ) rollover complexes containing phosphorus donor ligands , 2017 .

[84]  G. Deacon,et al.  Platinum Diolefin Complexes – Synthesis, Structures, and Cytotoxicity , 2015 .

[85]  Ben M. Webb,et al.  Protein structure modeling with MODELLER. , 2014, Methods in molecular biology.

[86]  G. Sheldrick.  A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[87]  C. Che,et al.  Observation of low-energy metal-metal-to-ligand charge transfer absorption and emission: Electronic spectroscopy of cyclometalated platinum(II) complexes with isocyanide ligands , 2002 .

[88]  G. Jaouen.  Bioorganometallics: Biomolecules, Labeling, Medicine , 1994 .

[89]  W. R. Wadt,et al.  Ab initio effective core potentials for molecular calculations , 1984 .

[90]  P. Treichel.  Transition Metal-lsocyanide Complexes , 1973 .